1Lee KR, Macfadyen RJ, Reid JI. Tissue angiotensin conveting enzyme in Hibition. Releveent To Clinical Practice. Am J Hypertens, 1990;3:2665～2725
2Johnston CI. Biochemists and pharmacology of the renin angiotension system. Durgs, 1990;39(suppl):321～315
3木宏实.动脉硬化:细胞分子生物学ゐろ病态治疗.1994;5:45
4Melby JC. Angiotensin-converting enzyine in cardiovascular and adrenal tissues and implications for successfud blood pressure menagement.Am J Cardiol, 1992;68(10):2C～7C
5Dzau VJ. Cardiac venin-angiotensin system. Molecular and functional aspects. Am J Med,1998;84(3A):22～27
4[3]Kwame O, Scott R, Trudy G, RN, Dara Schuster. Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic african americans[J]. Diabetes Care, 2004;27(6): 1439 - 46
5[4]David W, Dunstan, Paul Z, Zimmet, Timothy A. Welborn, et al. The Rising Prevalence of Diabetes and Impaired Glucose Tolerance[J]. Diabetes Care, 2002;25(5) :829 - 34
6[6]The diabetes prevention program (DPP) research group. The diabetes prevention program (DPP)[J]. Diabetes Care, 2002;25(12) :2165 - 71
7[7]Jakko T, Jaana L, Johan G, Eriksson, Timo T, Valle, et al.Finnish diabetes prevention study group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J]. N Engl J Med, 2001;344(18):1343 - 50
8[8]Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A,Laakso M. STOP-NIDDM trial research group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial[J]. Lancet, 2002;359(9323) :2072 - 7
9[11]The heart outcomes prevention study investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovasculor events in high-risk patients[J]. New Eng J Med, 2000;342(3): 149 - 53
10[12]Zachary T, Bloomgarden. Treatment of Type 2 Diabetes: The american association of clinical endocrinologists meeting [ J ].Diabetes Care, 2002; 25(9): 1644 - 9
